NeuroBo Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
NeuroBo Pharmaceuticals has been growing earnings at an average annual rate of 6.5%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
6.5%
Earnings growth rate
63.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -214.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation
Oct 03
NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Sep 29Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely
Sep 14NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split
Sep 12NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases
Nov 25NeuroBo on track to post a record gain after announcing a special meeting
Jun 14NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition
Jan 06Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like
Dec 21NeuroBo Pharmaceuticals EPS misses by $0.02
Nov 13Revenue & Expenses Breakdown
How NeuroBo Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -28 | 8 | 21 |
| 30 Jun 24 | 0 | -26 | 7 | 19 |
| 31 Mar 24 | 0 | -17 | 7 | 13 |
| 31 Dec 23 | 0 | -12 | 7 | 9 |
| 30 Sep 23 | 0 | -12 | 7 | 6 |
| 30 Jun 23 | 0 | -11 | 8 | 4 |
| 31 Mar 23 | 0 | -14 | 9 | 2 |
| 31 Dec 22 | 0 | -14 | 9 | 3 |
| 30 Sep 22 | 0 | -14 | 9 | 4 |
| 30 Jun 22 | 0 | -14 | 9 | 5 |
| 31 Mar 22 | 0 | -15 | 9 | 6 |
| 31 Dec 21 | 0 | -15 | 9 | 7 |
| 30 Sep 21 | 0 | -30 | 8 | 5 |
| 30 Jun 21 | 0 | -30 | 8 | 5 |
| 31 Mar 21 | 0 | -28 | 7 | 4 |
| 31 Dec 20 | 0 | -30 | 8 | 5 |
| 30 Sep 20 | 0 | -23 | 5 | 6 |
| 30 Jun 20 | 0 | -24 | 5 | 5 |
| 31 Mar 20 | 0 | -24 | 5 | 6 |
| 31 Dec 19 | 0 | -21 | 3 | 5 |
| 30 Sep 19 | 0 | -12 | 5 | -1 |
| 30 Jun 19 | 0 | -11 | 3 | -1 |
| 31 Mar 19 | 0 | -13 | 2 | 2 |
| 31 Dec 18 | 0 | -16 | 2 | 5 |
Quality Earnings: NRBO is currently unprofitable.
Growing Profit Margin: NRBO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NRBO is unprofitable, but has reduced losses over the past 5 years at a rate of 6.5% per year.
Accelerating Growth: Unable to compare NRBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NRBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: NRBO has a negative Return on Equity (-214.1%), as it is currently unprofitable.